Radiotherapy for Rhabdomyosarcoma: Indications and Outcome

This publication has 48 references indexed in Scilit:

• Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
• Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984–1997: A report from the Children's Oncology Group
  Pediatric Blood & Cancer, 2010
• Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
  Journal of Clinical Oncology, 2009
• Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group
  Journal of Clinical Oncology, 2009
• Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
  Journal of Clinical Oncology, 2001
• The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS‐I Through IRS‐IV Studies as Background for the Current IRS‐V Treatment Protocols
  Sarcoma, 2001
• The Third Intergroup Rhabdomyosarcoma Study.
  Journal of Clinical Oncology, 1995
• The PAX3-FKHR Fusion Protein Created by the t(2;13) Translocation in Alveolar Rhabdomyosarcomas Is A More Potent Transcriptional Activator than PAX3
  Molecular and Cellular Biology, 1995
• Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee.
  Journal of Clinical Oncology, 1990
• Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation.
  Journal of Clinical Oncology, 1988